gamma chain-transduced autologous hematopoietic stem cell therapy (Discovery Genomics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namegamma chain-transduced autologous hematopoietic stem cell therapy (Discovery Genomics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionIL-2RG gene transference
TargetsInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsSevere Combined Immunodeficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesDiscovery Genomics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDiscovery Genomics Inc
Active IndicationsN/A
Inactive IndicationsSevere Combined Immunodeficiency

Other Information

ATC CodeN/A
Related LinksN/A